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Abstract

Carbosilane dendrimers are a particular type of dendrimer structure that has been used as delivery
vehicles for drugs and nucleic acids. They have a defined structure according to their generation
number, and their terminal groups can be rendered cationic or anionic. The cationic charges can
address the limitation of electrostatic repulsion between the negatively charged phosphate groups of
nucleic acids and negatively charged cell membranes. Specific drugs can be loaded into the central part
of the dendrimer or attached at the exterior, and the overall positive charge may improve the efficacy
of anti-inflammatory drugs. One promising feature of dendrimers is their non-toxicity both in vitro and
in vivo up to therapeutic concentrations. Carbosilane dendrimers display good biocompatibility and can
be used for anti-HIV, anti-viral, and anti-inflammatory applications, as well as for delivery of nucleic
acids for anti-cancer therapy.
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1. Introduction

Dendrimers are nanosized branched molecules composed of a central core with dendrons extending
outward, similar to tree branches. The dendrimer molecules are designed to have a uniform molecular
weight and size according to their generation number. The terminal groups on the exterior can be
chemically modified or tailored according to the desired application [1]. Dendrimers can encapsulate
cargos or be chemically attached to different molecules according to the size, surface properties, and
functional groups present, and thereby protect these molecules against the adverse effects of external
factors. Furthermore, they can release these molecules within their targeted environment [[2], [3], [4]].
Poly(propylene imine) (PPI) and Poly(amido amine) (PAMAM) dendrimers are the two most studied
dendrimers, according to their commercial accessibility [5]. However, poly(l-Lysine) (PLL) [6],
phosphorous dendrimers (P-dendrimers) [7], and carbosilane dendrimers [8], are widely discovered.
These various groups of dendrimers were studied for their usage in different applications such as drug
and gene delivery systems, and antiviral and antibacterial agents [9].
Carbosilanes are compounds with elements silicon and carbon in the molecular skeleton. With the use
of silicon chemistry, various types of carbosilane dendrimere which have hydrophobic scaffolds and
high thermal stability have been developed [10]. The benefits of carbosilane dendrimers is related with
high energy of the C–Si bond, and also hydrophobicity. Although they can be changed into hydrophilic
materials by surface functionalization with polar moieties. Groups such as Si–Cl, Si–H, and Si–CH2CH
CH2can introduce various intriguing organic and inorganic substituents, and causes the increasing use
in biomedical fields [11].
Based on nature of the periphery, carbosilane dendrimer is divided into two types of cationic and
anionic dendrimers. The cytotoxicity of carbosilane dendrimers depends on the nature and number of
functional surface groups. Cationic carbosilane dendrimers show high toxicity, while anionic
dendrimers demonstrate low toxicity effects [12]. PAMAM dendrimer have terminal amines are
considered by toxicity based on generation, and carbosilane dendrimers terminated with neutral or
anionic groups show low toxicity [13]. Therefore, modification of the surface of the cationic dendrimer
with negatively charged or neutral moieties decreases its cytotoxicity.
In recent years, carbosilane dendrimers have demonstrated the potential for many applications such as
delivery of drugs and nucleic acid into cells, and treatment of diseases due to their good properties
[14,15]. Drug delivery systems are therapeutic carriers which suggestion various benefits than
conventional drugs applied for the treatment of infectious diseases and cancers. Different types of
delivery system used in biomedical application, such as nanoparticle, lipid-based materials, micelles,
dendrimers, etc. [16,17]. The good properties of dendrimers make them appropriated for the
treatment of infectious diseases and cancers. Reduced toxicity and side effects of drugs, increased
bioavailability, and increased half-life resulting in reduced kidney clearance are advantages of using

dendrimers as drug carriers [9]. However, carbosilane dendrimer can have antiviral activity in
combination with antiviral drugs and used as therapeutic agents in therapy of combination [18,19].
Cationic dendrimers have emerged as powerful platforms for the formation of dendriplexes due to the
electrostatic interaction with nucleic acids, including small interfering RNA (siRNA) and
oligonucleotides [20]. Cationic dendrimers including are increasingly being used in cell transfection
protocols. The water solubility of cationic carbosilane dendrimers allows them to be used as non-viral
carriers for drug and gene therapy, owing to their powerful amphiphilic behavior. However, evidence
suggests that the ammonium end groups of these carbosilane dendrimers need to be carefully
controlled to prevent toxicity. This intrinsic toxicity can possibly be addressed by binding to
polyethylene glycol (PEG). Cationic phosphorus dendrimers complexed with nucleic acids have been
shown to be able to serve as vehicles for siRNA and DNA delivery in vitro [[21], [22], [23], [24]].
Additionally, water-stable nanocarriers such as anionic carbosilane dendrimers have received
considerable attention, and their 1st to 3rd generation analogues can be synthesized to contain
sulfonate and carboxylate groups [25,26]. Second-generation carbosilane dendrimer functionalized
with sulfated (G2-S16) is an example of a second-generation anionic dendrimer that bears sulfonate
groups on the exterior with a silica-based core [27,28]. High biocompatibility is an important feature of
the G2-S16 anionic carbosilane dendrimer with 16 sulfonate groups. This polyanionic carbosilane
dendrimer has shown anti-HIV viral activity, thus addressing a major health concern. The
biocompatibility, low toxicity, and high inhibitory capacity are advantages for HIV inhibition. Maraviroc
is a chemokine receptor antagonist that has been designed to act against HIV by interfering with the
interaction between HIV and chemokine receptor type 5 (CCR5), and thereby blocking HIV from
entering human cells. The combination of polyanionic carbosilane dendrimer with naphthyl sulfonated
(G2-NF16) –and G3-S16 with maraviroc increased the antiviral potency against HIV [[29], [30], [31],
[32]].
In this review, we describe some applications of carbosilane dendrimers in biomedical fields and
nanomedicine, especially for anti-cancer therapy, immunotherapy, drug delivery, and gene therapy,
and highlight their importance in the treatment of the dread diseases, cancer and HIV/AIDS.

2. Chemistry of carbosilane dendrimers

Dendrimers are usually synthesized by one of two methods. The divergent method begins with the
core and proceeds radially outwards in defined generations, each of which adds an additional layer.
The second method was designed by Hawker, called the convergent method, starts by the synthesis
and connection of the outermost parts, and eventually adding a central core that connects all the
branches together. Other approaches that have been investigated for dendrimer synthesis include click
chemistry, total synthesis routes, double exponential, and hypercore and branched monomers [[33],
[34], [35], [36]].
The preparation of hybrid carbosilane-based dendrimers containing viologen and phosphorus-based
groups has been described using a convergent strategy based on the double alkylation of 4,4-bipyridine
units. The interaction of these hybrid dendrimer molecules with plasma proteins, such as human serum
albumin (HSA) and the impact of this on the hemotoxicity and cytotoxicity was investigated [37].
Hydrophilic dendrimers generally have different overall sizes, and show different reactions with HSA.

This is probably due to the size, rather than the number of positive charges according to zeta-potential
data. Measurement of the HSA fluorescence intensity and the Stern-Volmer quenching constant (Ksv)
revealed that the larger dendrimer interacted with the secondary structure of HSA to a greater extent
than the smaller dendrimer. The effects of these dendrimers on cell viability was evaluated using
eukaryotic cells (mouse fibroblasts). The cytotoxicity of these carbosilane viologen-phosphorus
dendrimers was associated with the outer positive charge, rather than internal charges; therefore they
may be suited to act as antibacterial compounds, or non-viral carriers for nucleic acids [37,38].
Biodegradable cationic carbosilane dendrimers can be prepared using two different approaches. The
first one uses a reaction with amine dendrons where the hydroxyl group is located at the focal point
and the dendrimers have Si–Cl peripheral bonds. The second method exploits the reaction of
dendrimers that have acidic peripheral groups to produce first alcohols then amines, and finally adding
MeI for quaternization of the neutral compounds to form cationic ones. However, the aryl groups
attached to the oxygen atoms (Si-OR) result in a reduced hydrolysis rate compared to compounds with
alkyl chains attached to oxygen atoms. Dendrimers with Si–O bonds are unstable in aqueous conditions
and hence these compounds are not appropriate for biomedical applications. Dendrimers that show
higher water stability are better suited as carriers for gene and drug delivery [[39], [40], [41], [42]].
Recent synthetic methods have been introduced involving hydrosilylation reactions via Cu-catalyzed
cycloaddition of azide-alkyne derivatives. This method enables the preparation of novel anionic watersoluble carbosilane dendrimers possessing carboxylate, phosphonate, naphthalenesulfonate and
sulfate terminal groups. One of the positive benefits of these anionic dendrimers is their non-toxicity in
both in vitro cell culture up to 20 μM concentration, and also in vivo. These dendrimers exhibited
inhibition of HIV infection in vitro in peripheral blood mononuclear cells (PBMCs) due to the presence
of anionic groups (carboxylate, naphthylsulfonate, and sulfate) [[43], [44], [45]]. Researchers have used
in vitro experiments and computer modeling to show that carboxylate-terminated carbosilane
dendrimers had the most significant interaction with proteins at acidic pH values, in comparison to
basic and neutral pH conditions. At acidic and neutral pH, carboxylate dendrimers can form a stable
complex with some proteins. This approach can be used for the purification of proteins from complex
mixtures at acidic pH, using carboxylate-terminated carbosilane dendrimers to carry out selective
protein enrichment [[46], [47], [48], [49]].
The click chemistry reaction has been used to prepare cationic carbosilane complexes by conjugating
azide-terminated carbosilane dendrimers to propargyl amines, followed by the subsequent addition of
methyl iodide for quaternization. Dendrimers have been developed as nanoparticles bound to plasmid
DNA, and the ensuing DNA dendritic nanoparticles (dendriplexes) demonstrate a good transfection
ability both in vivo and in vitro. Two different families of cationic carbosilane dendrimers have been
developed, where the first family possesses ammonium group on segments and can be first to third
generations. The second family contains two different atoms with positive charges. The second
generation of the first family (F1G2 5/1(±)) has been developed and evaluated for plasmid-mediated
gene transfer in HePG2 cells [[50], [51], [52], [53]].
Anionic carbosilane dendrimers with sulfonate or carboxylate groups have also been synthesized via
thiol-ene chemistry. The advantages of this method are more facile purification and shorter reaction
times, as compared with Michael-type hydrosilylation or the click chemistry with azide-alkyne linkages.

A comparison of silicone-core dendrimers and polyphenoxo-core dendrimers revealed that the
silicone-core second generation dendrimers 2 and 12 exhibited 85–90% HIV inhibition without any
inflammation or vaginal irritation in female mice. The poly-phenoxo-core dendrimers showed lower
biocompatibility. The silicone-core dendrimers could be promising candidates as topically applied
microbicides against HIV [31,[54], [55], [56]].
A new class of cationic carbosilane dendrimers that were functionalized with varying peripheral
phosphonium groups were synthesized, and their toxicity was evaluated using CV and MTT assays in
cell lines (NRK, BRL, B14 cells). The cytotoxicity of carbosilane dendrimers bearing methyl groups
displayed enhanced toxicity compared to dendrimers bearing different alkyl substituents (PBu3 and
P(Et2)2 (CH2)3)OH). P(C₆H₄-OMe)₃ dendrimers demonstrated very low toxicity towards the range of cell
lines. Overall, phosphonium-substituted carbosilane dendrimers could be a potential alternative to
ammonium-substituted dendrimers for gene therapy applications [[57], [58], [59], [60]].
The multivalency of carbosilane dendrimers plays an important role in the antimicrobial activity of
these compounds. Quaternary ammonium (QA)-functionalized carbosilane dendrimers showed higher
microbicidal activity compared to monofunctional carbosilane dendrimers, as illustrated by
ammonium-terminated hyperbranched polycarbosilane (PC) dendrimers [61]. Poly(propyleneimine)
(PPI) dendrimers showed only a low antimicrobial activity, whereas ammonium-terminated
Poly(propyleneimine) (PPI) dendrimers had higher antimicrobial activities [62]. Anionic carbosilane
dendrimers bearing carboxyl and sulfonate groups have demonstrated anti-HIV activity. These
compounds showed 100% vital inhibition and could act as antiretroviral drugs in TZM-bL cells [[62],
[63], [64]].

3. Application of carbosilane dendrimers in biology and nanomedicine

Carbosilane dendrimers, which are hyperbranched macromolecules, have attracted researchers’
attention over the last two decades due to their various characteristics, in the fields of biology and
nanomedicine such as anticancer therapy, immunotherapy, and drug/gene delivery [8,65,66]. The
existence of cationic groups on carbosilane dendrimers renders them water-soluble. The amphiphilic
characteristics of carbosilane dendrimer make them important drug carriers. Thanks to the abundance
of end groups, a high loading of drug or nucleic acid molecules can be attached by covalent bonds
and/or by electrostatic interactions, thus making them a suitable choice for drug and gene delivery
[30,[67], [68], [69]]. In the following sections, different application of carbosilane dendrimers have
been introduced.

3.1. Application of carbosilane dendrimers in anticancer therapy and immunotherapy

Cancer patients often need high dosages of chemotherapeutic drugs, which tend to have unacceptably
high toxicity. Moreover, these drugs have no specificity for tumors, and will cause serious damage to
normal tissues such as heart, liver and lungs. The low molecular weight of many cytotoxic drugs and
their lack of specificity, have led to searches for better ways to deliver them in a more selective
manner. Dendrimer can be a good choice as anticancer agent, and some studies have been conducted
on the role of carbosilane dendrimers in cancer therapy and immunotherapy [[70], [71], [72]] (see Fig.
1).

Carbosilane dendrimers that have been functionalized with N-, NH2-donor monodendate ligands and
N,N-chelating ruthenium complexes are a new approach in anticancer therapy. The rutheniumterminated carbosilane dendrimers (CRD27 and CRD13) showed the most homogenous formulation.
The cytotoxicity of CRDs towards cancer cells and normal cells, hemolytic activity, and biophysical
characterization were examined. The zero generation metallodendrimers were effective drugs,
because they were non-toxic to normal cells, but were still cytotoxic to cancer cells. CRDs were found
to be effective against an acute promyelocytic leukemia cell line (HL60) [65] (Fig. 2).

Fig. 1. Synthesis of carbosilane dendrons (generations 1–3) [15].

Fig. 2. Structures of 3 newly synthesized classes of CRDs with imine-pyridine groups (CDR5, CRD14 and CRD28),
pyridine-imine groups (CRD7, CRD13andCRD27), and ANH2 groups (CDR34 and CRD32) [65].

Dendritic cells (DCs) are an important class of antigen-presenting cells (APC), because they can activate
adaptive immune cells (T-cells and B-cells) to recognize tumor antigens [73]. Innate immune cells,
including many subsets of monocytes, macrophages and DCs can mediate the non-specific immune
response against microbial invaders, but DCs in particular can stimulate the adaptive immune response
through antigen presentation [74].
In one study, dendrimers were designed as a vehicle for HIV-1 specific peptides. The goal was to trigger
an adaptive immune response against HIV-1 by delivering the peptides to DCs. The cationic carbosilane
dendrimer (G2-NN16) was loaded with several HIV derived-peptides (p24/gp160/NEF or p24/gp160).
The G2-NN16/peptide complex alone showed better uptake by immature DCs compared to mature
DCs. The peptides did not affect the ability of DCs to migrate to draining lymph nodes. Molecular
dynamic simulations revealed that the peptides inhibited the cell uptake of other peptides, for
example NEF peptide prevented the binding of gp160 to G2-NN16. This showed that G2-NN16 could
not act as a vehicle for delivery of two or more HIV-derived peptides to DCs [[75], [76], [77]].

Tumor-associated macrophages (TAMs) are found within tumors. TAMs with a M2 polarization express
immunosuppressive chemokines, cytokines, and proteases including MMPs. These macrophages play
an important role in the processes of angiogenesis and tumor metastasis, and are considered to be
target prevent tumor progression [[78], [79], [80], [81]]. Carboxylate-functionalized dendrimers could
have a role in restricting the signaling pathways and reducing TAM function. To investigate the
potential role of dendrimers in tumor immunotherapy, the effect of G3O3(SiONN)24 (2G-03NN24) on
M2 macrophage polarization was studied. It was claimed that the 2G-03NN24 dendrimer reduced the
LPS-induced 1L-10 production from monocyte-derived M2 macrophages. Moreover 2G-03NN24 could
switch the gene expression profile towards the M1 polarization pattern, by increasing markers such as
1NHBA, FLT1, SERPINE1 and EGLN3, and decrease markers of M2 polarization, such as IGF2, EMR1,
SLC40A1 and FOLR2. It was shown that the 2G-03NN24 dendrimer decreased STAT3 activation. Overall,
the results showed that the 2G-03NN24 dendrimer could be used for antitumor therapy owing to its
ability to reduce the M2 polarization state of TAMs [66,[82], [83], [84]] (Fig. 3).

Fig. 3. Schematic illustration of the decrease in the function of M2 macrophages and switching gene expression
of M2 macrophages to M1 polarization state by 2G-03NN24 dendrimer [66].

3.2. Application of carbosilane dendrimers in drug and peptid delivery

Carbosilane dendrimers can be used as carriers in drug delivery by attaching chemical groups to the
surface of the macromolecules. Drug delivery systems are probable therapeutic vehicles which suggest
various benefits than conventional drugs applied for the treatment of diseases. A best drug delivery
system must be capable to decreases drug toxicity, and enhanced biocompatibility, bioavailability and
drug solubility [16]. Dendrimers are synthetic polymers with branched macromolecules and made up
of the interior and exterior layers. Encapsulation of drugs occurs in the interior layers, decreasing
toxicity and control release of drugs; and the exterior layer is composed of functional groups which are
suitable for conjugation of drugs. Therefore, this properties of dendrimers make them beneficial as a
drug delivery systems and they are being studied by many scientists [9].
Ibuprofen-modified dendrimers and dendrons (including cationic-ibuprofen dendrimer and dendrons)
can improve the performance of the anti-inflammatory drug, ibuprofen by improving its uptake by
cells. Cationic carbosilane dendrimers and dendrons can be loaded with ibuprofen, either within the

central core or by attachment to the outer reactive groups. Ibuprofen can be attached via ester bonds,
which can be cleaved to release the anti-inflammatory drug. Cationic ibuprofen-conjugated
dendrimers/dendrons demonstrated higher anti-inflammatory responses compared to free ibuprofen.
The ibuprofen-conjugated dendrons (IboCO2G3(NMe+3)8) decreased inflammatory responses and
lowered the secretion of several inflammatory cytokines, including IL-1β, TNFα, IL-6, and CCL3 and
decreased the LPS-induced expression of COX-2 [14,21,22,85,86] (Fig. 4).

Fig. 4. Schematic illustration of ibuprofen-conjugated cationic carbosilane dendrimers/dendrons and their
impact on the anti-inflammatory function of ibuprofen [14].

Peptides and proteins are delivered as complexes with carbosilane dendrimers or dendriplexes. In
dendriplexes, a cargo can be bound by electrostatic interactions and protected by dendrimer structure.
Ionov et al. showed the complexation of HIV-derived peptides (Gp160, P24, and Nef) with cationic
carbosilane dendrimers (CBD-OS and CBD-CS). This formulation was ready in molar ratio (2.5–3):1 of
dendrimer: peptide with size range of 180–275 nm. The dendrimers were terminated with amino
groups that are appropriate for binding the HIV derived peptides with negatively charge and for the
delivery of HIV peptides to DCs [87].
Dendriplexes were formed by interactions between HIV-derived peptides and two different types of
positively charged carbosilane dendrimers. The researchers then investigated the interactions that
occurred between these dendriplexes and model lipid bilayer membranes that formed negatively
charged vesicles. Negatively charged vesicles composed of a mixture of DMPC/DPPG showed the
strongest interaction accompanied by an increase in fluorescence anisotropy of a probe localized in the
polar domain of the lipid bilayer. There was also an increase in the surface pressure of the lipid
monolayers. Carbosilane dendrimers could be used for delivery of HIV derived peptides into cells for
vaccine purposes [88] (Fig. 5).

Fig. 5. The formation of HIV-peptide/dendrimer complexes to deliver HIV-peptides into cells [88].

3.3. Application of carbosilane dendrimers in the treatment of viral infection

Many studies have been conducted to assess the effect of carboxylated dendrimers on viral infections
such as HIV, herpes simplex virus (HSV) infections and influenza [19,89]. Polyanionic carbosilane
dendrimers (PCDs) used alone could be improved microbicides to prevent HIV transmission. Moreover,
PCDs could also be used as drug-delivery vehicles for anti-viral drugs such as maraviroc (MRV) or
tenofovir (TFV), and their combinations could show a synergistic anti-HIV activity. The synergistic
combination provided greater efficacy than monotherapy with drugs or dendrimers alone.
Combinations of PCD generations 1 or 2 plus MRV or TFV were investigated for preventing viral
transmission of HIV and HSV-2. According to the results, the best candidate to prevent sexual
transmission of HIV-1 was the dendrimer plus MRV, and the dendrimer combination with TFV was best
to suppress HSV-2 [19].
Another study used CalcuSyn software to analyze the combination of dendrimers and TFV complexes.
The inhibition of HIV-2 infection under different in vitro conditions was probed, including virus
inactivation, reduced cell fusion, reduced internalization by PBMCs, and inhibition of attachment. The
results revealed that the second and third-generation carbosilane dendrimers with a silicon atom core
and 16 sulfonate (G2-S16), napthylsulfonate (G2-NS16), and sulfate (G3-sh16) dendrimers inhibited
HIV-2 viral proliferation in vitro. The synergistic interaction of the triple combination, dendrimers plus
tenofovir plus raltegravir, led to increased anti-HIV-2 activity. In vivo studies in female BALB/C mice,
using vaginal application of 3% G2-s16 for 2 days, showed there was no vaginal irritation. According to
these results, anti-HIV-1 and anti-HIV-2 activities were demonstrated by the G2-S16, G2-NS16, and G3sh16 dendrimers. G2 and G3 indicate the 2nd and 3rd generation dendrimers, while Sh16, NS16, S16
possessed sulfate, naphthylsulfonate and sulfonate terminal groups respectively [90].
One obstacle against the effectiveness of topical vaginal gels that have been employed in vivo to inhibit
HIV-1 infection is the existence of amyloid fibrils within semen. Human semen contains peptides
capable of forming amyloid fibrils called semen-derived enhancer of viral infection (SEVI) that can
greatly increase HIV infection rates. In the presence of SEVI added to TZM-bl cells in culture, the HIV
infection rate was increased, and although the IC50 values were both increased for 2 s and thirdgeneration polyanionic carbosilane dendrimers functionalized with 16 sulphonated end groups (G2STE16 and G3-S16), nevertheless the protective rate was maintained up to 90%. When the dendrimers
were combined with TDF/MVC the anti-HIV-1 effects were improved by up to 7-fold in the presence of
SEVI. These results showed a synergistic effect between polyanionic carbosilane dendrimers and
antiviral drugs to overcome the undesirable effects of amyloid fibrils [[91], [92], [93]].
The combination of polyanionic carbosilane dendrimers with antiretroviral (ARV) drugs could act as
novel microbicides against HIV. Double or triple-combinations of dendrimers and ARVs could inhibit
HIV-1 in the early stages of replication. This activity is preserved in seminal fluid or in acidic
environments, without causing any inflammatory response. The most effective combination was
observed with the G2-STE16 dendrimer. Moreover, no irritation was found in female mice after vaginal
administration [94].
Anionic carbosilane dendrimers functionalized with sulfonate (G3-S16) or naphthyl sulfonate (G2-NF16)
terminal groups in combination with different ARVs have been tested for HIV-1 prophylaxis. G3S16/EFV and G2-NF16/TFN achieved the best profile against the X4 and R5-HIV-1 strains. Experiments

were conducted in human cell lines that were tropic for R5 and X4 HIV-1 strains, revealed that G2-NF16
and G3-S16 dendrimers had synergistic or additive effects with efavirenz, tenofovir, and zidovudine
(EFV, TFV, AZT) in the composite system. The combination of polyanionic carbosilane dendrimer with
EFV, TFV, AZT showed better antiviral activity compared to single components [[95], [96], [97]].
The 2G-S16 dendrimer could act as a safe and effective topical microbicide against HIV-1 and HIV-2.
2G-S16 protected the epithelial monolayer from cell disruption, consequently, it can block HIV entry. It
can also create protection against X4, R5 and X4/R5 HIV strains infecting or co-infecting PBMCs. The
combination of 2G-S16 with tenofovir or maraviroc resulted in 100% HIV-inhibition and showed a
synergistic profile at low doses against a set of HIV strains. After administration of different daily
concentrations of 2G-S16 over 7 days, there were no side effects or irritation in the female rabbit
genital tract [[98], [99], [100]].
As mentioned, triple combinations can protect against HIV-1 infection in seminal fluid or in an acid
environment more effectively than a single drug. The three-drug combination G2-STE16/G2S16/maraviroc, G2-STE16/G2-S24P/tenofovir and G2-STE16/tenofovir/maraviroc at 10:10:1, 2:2:1 and
10:5:1 ratios, showed impressive antiviral potency. With a lack of inflammation or irritation in female
mice, the triple combination (carbosilane dendrimer, TFN, MRV) could be a good candidate for topical
application [101,102].
Blocking the interaction between gp120/CD4 and HIV is an important strategy to protect against HIV
infection. The second–generation polyanionic carbosilane dendrimer G2-S16 with a silica core was
designed for this purpose. In vivo studies revealed 84% inhibition of HIV-1 transmission in humanized
(h)-BLT mice, without any detectable HIV-1 RNA and no vaginal lesions after topical vaginal
administration of 3% G2-S16. Dendrimers can also inhibit cell-to-cell HIV-1 transmission, showing thier
multifunctional capability to block HIV-1. To maximize acceptability, safety, and activity the dendrimer
could be administered in a novel formulation as a locally applied solid film. This novel dendrimer could
be a promising solution to prevent transmission of HIV-1 [[103], [104], [105]].
The worldwide spread of hepatic C virus (HCV) has led to the development of new drugs that act as
direct antiviral agents (DAAs), but owing to the advent of drug-resistant virus variants, and the
difficulty of using these drugs in less developed countries, newer antiviral approaches are being
sought. Polyanionic carbosilane dendrimers (PCD) can destabilize infectious virions. Anionic polymers
like heparin have been shown to inhibit both HCV and HIV, mainly by interfering with the ability of the
virus to gain entry to the cell. The anti-HCV second generation carbosilane dendrimer consisted of a
polyphenolic core with 24 sulfonate groups on the surface [106].
A series of carbosilane dendrimers that had all been functionalized with hemagglutinin (HA) binding
peptide (Ala-Arg-Leu-Pro-Arg) was systematically synthesized, and studied for their ability to inhibit
influenza viruses. The peptide sequence acted as a sialic acid peptide mimetic. The carbosilane-based
peptide dendrimers, unlike sialylated dendrimers, could not be digested by viral neuraminidases. The
dumbbell-type of peptide dendrimer induced the best inhibitory activities against two human influenza
viruses, A/Aichi/2/68 (H3N2) and A/PR/8/34 (H1N1). The dumbbell-type dendrimer peptide showed
IC₅₀ values with the highest activity against both strains [107] (Fig. 6).

Fig. 6. Carbosilane dendrimers functionalized with HA-binding peptide and anti-influenza virus activity [107].

3.4. Application of carbosilane dendrimers in gene delivery

Gene therapy holds great promise for treatment of a wide range of diseases, such as cancer, viral
infections and genetic disorders [108,109]. Carbosilane dendrimers are among the promising novel
non-viral carriers that have been investigated for the safe and effective transfer of nucleic acids into
cells or tissues. Amphiphilic dendrimers that possess both hydrophilic and hydrophobic groups could
serve as a vector for gene transfer [110,111]. Carbosilane dendrimers have intrinsically hydrophobic
sections and hydrophilic PEG-conjugated dendrons can be attached by efficient click chemistry. Alkyne
PEG-based dendrons and azide carbosilane dendrons (generation 1 and 2) can be attached at the
periphery with NHBoc protection to provide cationic dendrimers with 6 or 8 ammonium groups. The
carbosilane dendrimer (generation 3) produced only a very low yield. These hybrid dendrimers were
active in PBMC. As a consequence of the presence of PEG, the dendrimers showed lower cytotoxicity
but weaker interactions with siRNA, as compared to the homodendrimer. The amount of PEG needs to
be carefully optimized for application as a nucleic acid nanocarrier [15].
Three different types of cationic dendrimers (phosphorus, carbosilane, PAMAM) were investigated for
the delivery of siRNAs for anti-cancer therapy, and also protects the siRNA from destruction by
nucleases [20,112]. The siRNAs were designed to down-regulate the pro-survival and anti-apoptotic
genes, siMcl-1, siBcl-xL, and siBcl-2. The dendrimer siRNA complexes were characterized using
transmission electron microscopy (TEM), fluorescence, circular dichroism (CD), gel electrophoresis,
dynamic light scattering and Zeta potential methods. All dendrimers could form complexes with siRNA
and protected the siRNA from RNase A-mediated degradation. The results showed that the siRNAdendrimers complex were more effective than only siRNAs, allowing one to reduction siRNAs
concentration in the targeted cells. As shown in Fig. 7, siRNAs is maintained from destruction by
enzyme in the presence of dendrimers, and duplex siRNA can be released from dendriplexes after
heparin treatment. In fact, the carbosilane and PAMAM dendrimers were best in preserving the siRNA
structure [113].

Fig. 7. Combination of dendrimers and siRNA form stable dendriplexes to protect siRNAs from nuclease
degradation [113].

The administration of siRNA can also be used to down-regulate the expression of viral-associated
genes. It has been shown that carbosilane dendrimers could deliver specific anti-viral siRNAs to
astrocytes and block HIV expression. The siRNA carbosilane dendriplex could target HIV-1 infected cells
within the CNS without causing cytotoxicity, and may have a role in treating neuro-AIDS and other
neurological disorders [114].
Due to the difficulties encountered in transfecting CD4 T-lymphocytes using non-viral vectors, the
second-generation carbosilane dendrimers 2G- [Si{O(CH2)2 N(Me)2 +(CH2)2NMe3 +(I−)2}]8 (2G-NN16)
and [G2O3(SiONN)12]24+(2G-03NN24) were investigated for their ability to transfect CD4 T lymphocytes
with siRNA against the Nef HIV-1 gene. Dendrimers were also tested on macrophages to determine
whether they could modify macrophage phenotype and induce an inflammatory response. The studies
showed the highest inhibition of HIV-1 replication was produced by the dendriplex formed by 2GO3NN24/siRNA-Nef. Dendriplexes did not trigger CD4 T lymphocyte proliferation and decreased TNFα
and IL-12p40 release from macrophages. The specific ability of the 2G-03NN24 dendrimer to decrease
CCR2 and CCL2 expression in macrophages confirmed their utility. Both 2G-NN16 and 2G-03NN24
carbosilane dendrimers could be used as siRNA carriers against HIV infection [115].
The delivery of siRNA can be facilitated by the use of micelle-forming amphiphilic carbosilane dendrons
as delivery vehicles. To characterize the binding between cationic dendrons and SiRNA molecules, the
pro-apoptotic siRNA called MC1-1 was used as a model compound. In this study, siRNA binding through
dendrons is the product of micelle formation. Carbosilane dendrons with generation 1–3 were
modified with hexanoic acid or palmitic acid grops. The binding of siRNA modified was similar between
the two different fatty acids, but did depend on the dendrimer generation (G1«G2<G3) [116].
The nanoparticles -based hybrid materials have been characterised and their properties as gene
delivery carriers, displaying a higher DNA adsorption ability and transfection efficiency. Functionalized
of the nanomaterials such as inorganic and polymeric nanoparticles with the various generation of a

dendron presented good DNA binding properties [117,118]. Mesoporous silica nanoparticles (MSNs) is
pretty candidate to be applied in nanomedicine, due to probability of controlling their size, their
tuneable pore diameter, and easy functionalization of the nanoparticles surface [119]. Carbosilane
dendrimers are applied as nontoxic materials to decorate nanoparticles in the search of drug/gene
delivery systems. The presence of a pore network inside the silica matrix can be applied to house
various agent into the mesopores with the purpose of reaching a multiple delivery [117]. Mesoporous
silica nanoparticle (MSNs) that have been decorated by carbosilane H3N +G2 (N+Me3)4 (8 or G2+) and
(EtO)3SiG3 (NMe2)8 (10 or G3) dendrons could transport single-stranded oligonucleotides into cells,
while at the same time having the potential to deliver other drugs incorporated into the silica
mesopores (Fig. 8). The cationic charge overcomes the problem of electrostatic repulsion between the
negatively charged nucleic acid strands and the negatively charged cell membrane. By using a human
osteoblast-like cell line as an in vitro model, the hybrid dendrimers were found to be non-cytotoxic,
and could efficiently deliver oligonucleotide DNA into the cells [117] (Fig. 8).

Fig. 8. Schematic illustration of functionalization of MSNs with carbosilane dendrons [117].

Another type of hybrid nanoparticle could be constructed by covalently attaching carbosilane
dendrimers to polymeric nanoparticles. Poly(d,l-lactide-co-glycolide) acid (PLGA) nanoparticles were
prepared with a controlled size using nano-emulsion templating and low-energy emulsification
methods. A carbodiimide-mediated coupling reaction was used to functionalize the nanoparticles with
a cationic carbosilane dendrimer. Antisense oligonucleotides could be complexed to the nanoparticle
surface by electrostatic interactions. These complexes were non-toxic and non-hemolytic at the
required concentrations, and allowed efficient antisense-mediated gene silencing [118] (Fig. 9).

Fig. 9. Schematic illustration of formation of nanoparticles by nano-emulsion and functionalization with
dendrimers as a non-viral gene delivery vectors [118].

Biodistribution studies are more accurate when the dendrimers are modified with fluorescent labels. In
one study, fluorescein-labeled cationic carbosilane dendrimers were developed that could form a
stable dendriplex with siRNA Nef and also possessed the ability to cross the blood brain barrier in a
mouse model. To label the dendrimer with fluorescein, first thiol groups were attached to vinylterminated dendrimers. Next the thiol groups were converted to –NH3 groups and –NMe₂ groups.
These were reacted with FITC followed by quaternization with MeI. Dendriplexes were then formed
with siRNA Nef that had been labeled with a second fluorescent reporter dye, Cy5.5. These
dendriplexes were characterized by electrophoresis and found to be non-toxic in vitro. Fluorescent
imaging showed that the dendriplexes were able to deliver siRNA Nef to the kidney, liver and lymph
nodes, compared to siRNA alone [120] (Fig. 10).

Fig. 10. Formation of dendriplexes with siRNA Nef and testing in a BALB/c mouse model [120].

3.5. Application of carbosilane dendrimers for other biomedical applications

Dendrimers have been investigated for the treatment or prevention of neurological and degenerative
brain diseases. One major problem in the treatment and/or prevention of central nervous system
diseases is the poor penetration of drugs through the blood-brain barrier. These problems can be
circumvented by the use of nanocarriers such as dendrimers [121]. Carbosilane dendrimers were
investigated for their potential to treat or prevent processes linked to Parkinson's disease. One study
used the mouse hippocampal cell line (MHippOE-18) to test whether carbosilane dendrimers could
protect the cells from rotenone-induced damage, and to prevent the fibril formation of α-synuclein
(ASN). Carbosilane dendrimers could prevent ASN fibril formation by interacting with the soluble
protein. When MHippoE-18 cells were pre-incubated with carbosilane dendrimers before adding
rotenone, the mitochondrial membrane potential was maintained, the levels of cellular ROS cells were
reduced, and the viability was enhanced. The different surface functional groups carbosilane
dendrimer did not make any significance different. Carbosilane dendrimers could be a valuable
pharmacological strategy to combat neurodegenerative disorders [122] (Fig. 11).

Fig. 11. Role of carbosilane dendrimers to prevent the formation of ASN fibrils and prevent cells from rotenoneinduced damage [122].

In view of the good water-solubility of cationic and anionic carbosilane dendrimers (generation 1–3),
they could be formulated as eye drops, containing a mucoadhesive polymer preparation. Anionic
carbosilane dendrimers terminated by carboxylate groups, and cationic carbosilane dendrimers with
ammonium groups have been investigated. To investigate the hypotensive effects of carbosilane
dendrimers loaded with acetazolamide (ACZ, a poorly water-soluble drug with low biological
permeation) an eye drop formulation was evaluated after intraocular installation in normotensive
rabbits. Both cationic and anionic carbosilane dendrimers demonstrated non-toxicity, and were
tolerated in a concentration range between 5 and 10 μM. The generation 3 positively charged
carbosilane dendrimer showed a good interaction with ocular mucins, using a biosensor evaluation.
Carbosilane dendrimers could increase the bioavailability of topical drugs administered in the eye at a
safe concentration level. Shortening the onset time and increasing the duration of the hypotensive
effects of acetazolamide were notable advantages of this approach [123].

4. Conclusions

Considering all of the above evidence, it appears that carbosilane dendrimers could be suitable
candidates for antiviral therapy, antitumor therapy, immunotherapy, and for gene and drug delivery.
Dendrimers can be tailored to have different generation numbers, and therefore different molecular
weights and sizes. The core and the periphery of the dendrimers are very different environments, and
hydrophobic molecules can be incorporated inside the core. The periphery can be functionalized with
either cationic or anionic groups to provide water-solubility, and very different biological properties
depending on the surface charge. Various molecules can be attached to the peripheral groups using
either charge-mediated electrostatic interaction to form complexes, or else covalent chemical bond
formation to form conjugates. One of the best examples of complex formation is that between cationic
carbosilane dendrimers and negatively charged nucleic acids such as DNA oligonucleotides or antisense
or small interfering RNA molecules. These complexes are called dendriplexes, and can protect the
nucleic acids against degradation and markedly increase the cell uptake. Several studies have

investigated the dendrimers as topical anti-HIV virucidal preparations for intravaginal application,
either alone or combined with anti-retroviral drugs. Anti-cancer applications, and routes to improve
vaccine delivery have also been studied. Despite the fact that there are several other dendrimer
backbones now available with different chemical structures, we believe that carbosilane dendrimers
may have advantages over these other compositions, that will be made clearer with further research in
the future.
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